Sulforaphane controls sugar and fat metabolism in obese mice by lowering stress signals and boosting insulin and FGF21 pathways

Daily treatment with 10 mg/kg body weight of sulforaphane significantly reduced complications of obesity in mice over 8 weeks.

• Sulforaphane may alleviate nonalcoholic fatty liver disease (NAFLD) and inflammation associated with obesity.
• Treatment is linked to reduced oxidative stress and adipose tissue enlargement.
• Insulin resistance may be improved through the regulation of glucose and lipid metabolism.
• Sulforaphane is associated with deactivating a specific protein that inhibits insulin signaling.
• It may also help in overcoming resistance to a hormone involved in glucose metabolism.

Simplified